BIOAGE LABS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
BIOAGE LABS, INC. (BIOA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 16.98 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-05
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 14.89K shares, a 73.43% decline year-over-year.
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 2.09K shares, a 98.81% decline year-over-year.
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 66.90K shares, a 383.93% increase year-over-year.
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 0.00 shares.
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 297.86K shares, a 353.18% increase from fiscal 2024.
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 65.73K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 14.89K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 16.98K shares 10-Q · filed 2026-08-05 | 83.88K shares derived: sum of 3 quarters · filed 2026-08-05 | 83.88K shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 2.09K shares 10-Q · filed 2026-05-08 | 68.99K shares derived: sum of 2 quarters · filed 2026-05-08 | 68.99K shares derived: sum of 3 quarters · filed 2026-05-08 | 125.04K shares derived: sum of 4 quarters · filed 2026-05-08 |
| 2025-12-31 | 66.90K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | 66.90K shares derived: sum of 2 quarters · filed 2026-03-24 | 122.95K shares derived: sum of 3 quarters · filed 2026-03-24 | 297.86K shares 10-K · filed 2026-03-24 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 56.05K shares derived: sum of 2 quarters · filed 2025-11-06 | 230.96K shares 10-Q · filed 2025-11-06 | 244.78K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 56.05K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 230.96K shares 10-Q · filed 2025-08-06 | 244.78K shares derived: sum of 3 quarters · filed 2025-08-06 | |
| 2025-03-31 | 174.91K shares 10-Q · filed 2025-05-06 | 188.73K shares derived: sum of 2 quarters · filed 2025-05-06 | ||
| 2024-12-31 | 13.82K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 65.73K shares 10-K · filed 2025-03-20 | ||
| 2024-09-30 | 51.90K shares 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |